Cardiovascular disease constitutes the leading
cause of death in the U.S. According to
the American Heart Association, approximately
870,000 lives are lost annually due to
cardiovascular disease. An estimated 58
million Americans suffer from cardiovascular
disease and the cost of this disease in the U.S.
is estimated at over $300 billion per year.
Chikujee has the opportunity to develop new
targeted nanoparticle therapeutics that will
detect and deliver drugs directly to the site of
cardiovascular disease. These next generation
multifunctional nanobindi technology not only
will detect the disease sites but will also
deliver the drug on demand and monitor its
efficacy at the disease site.
Product Portfolio
Cardio-Pac:
Paclitaxel based multifunctional NanoBindi
Cardio-Doc:
Docetaxel
based multifunctional NanoBindi
